In a randomized trial, intramuscular gentamicin was especially poor at curing rectal and pharyngeal gonorrhea infections.
Rapid development of antibiotic-resistant Neisseria gonorrhoeae hampers effective control efforts (the current recommended therapy is a single 500-mg dose of intramuscular [IM] ceftriaxone). To investigate gentamicin as an alternative, investigators conducted a randomized noninferiority trial of ceftriaxone versus a single 240-mg IM dose of gentamicin in 720 participants (mean age, 30; 81% men) with positive tests for genital, pharyngeal, or rectal gonorrhea who were recruited at 14 sexual-health centers in England.
Overall, infection had cleared at 2 weeks in 98% of the ceftriaxone group compared with 91% of the gentamicin group; however, the adjusted risk difference of 6.4% in favor of ceftriaxone did not meet the prespecified noninferiori…
Reviewing Author
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)